Article
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
The Lancet. Oncology - 1 Jun 2020
Abou-Alfa Ghassan K, Macarulla Teresa, Javle Milind M, Kelley Robin K, Lubner Sam J, Adeva Jorge, Cleary James M, Catenacci Daniel V, Borad Mitesh J, Bridgewater John, Harris William P, Murphy Adrian G, Oh Do-Youn, Whisenant Jonathan, Lowery Maeve A, Goyal Lipika, Shroff Rachna T, El-Khoueiry Anthony B, Fan Bin, Wu Bin, Chamberlain Christina X, Jiang Liewen, Gliser Camelia, Pandya Shuchi S, Valle Juan W, Zhu Andrew X
Abstract excerpt
BACKGROUND: Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome. The aim of this international phase 3 study was to assess the efficacy and safety of ivosidenib (AG-120)-a small-molecule targeted inhibitor of mutated IDH1-in patients with previously treated IDH1-mutant cholangiocarcinoma....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.